News AI health tech Respiree closes $11.6m Series A Health tech Respiree, developer of AI platforms to manage disease progression, has announced the successful closing of an $11.6m Series A financing.
News FDA approves Respiree’s cardio-respiratory wearable The real-time sensor can be used to spot exacerbations of COPD days in advance, says company.
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.